Physician profile

Keith E Mcmanus

Family Medicine · Denver, NC

NPI 1477563229

$294.05

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$19.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $60.29 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $56.71 2021
Abbott Laboratories $36.68 2021-2023 Freestyle Libre 3
Lilly USA, LLC $28.39 2021
Boehringer Ingelheim Pharmaceuticals, INC. $21.98 2021
Organon LLC $19.11 2021
Genentech USA, INC. $15.24 2020
Janssen Pharmaceuticals, INC $14.90 2021
Gilead Sciences, INC. $14.07 2019
Pfizer INC. $13.62 2022
Merck Sharp & Dohme LLC $13.06 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Keith E Mcmanus

$294.05

in general payments reported 2019-2025

Years
2019-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/66875/keith-e-mcmanus

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.